drugset
drugset / Trial / NCT02134288

Belatacept for Renal Transplant Recipients With Delayed Graft Function

NCT02134288 ↗

Phase 0 Terminated 8 enrolled Ohio State University Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Currently looking for individuals that have received a kidney transplant, are experiencing delayed graft function (DGF), and meet the criteria for study participation.

Timeline

Start
2014-04
Primary completion
2018-12-11
Completion
2019-01-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Belatacept Protein / enzyme biologic 5 mg/kg Intravenous
Comparator Everolimus Small molecule 1.5 mg/kg Oral

Indications

No indication recorded.